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Abstract
Background: There are numerous challenges in including patients in a core outcome set (COS) study, these can
vary depending on the patient group. This study describes current efforts to include patients in the development of
COS, with the aim of identifying areas for further improvement and study.
Methods: Using the COMET database, corresponding authors of COS projects registered or published from 1
January 2013 to 2 February 2017 were invited via a personalised email to participate in a short online survey. The
survey and emails were constructed to maximise the response rate by following the academic literature on
enhancing survey responses. Personalised reminder emails were sent to non-responders. This survey explored the
frequency of patient input in COS studies, who was involved, what methods were used and whether or not the
COS development was international.
Results: One hundred and ninety-two COS developers were sent the survey. Responses were collected from 21
February 2017 until 7 May 2017. One hundred and forty-six unique developers responded, yielding a 76% response
rate and data in relation to 195 unique COSs (as some developers had worked on multiple COSs). Of focus here are
their responses regarding 162 COSs at the published, completed or ongoing stages of development. Inclusion of
patient participants was indicated in 87% (141/162) of COSs in the published completed or ongoing stages and
over 94% (65/69) of ongoing COS projects. Nearly half (65/135) of COSs included patient participants from two or
more countries and 22% (30/135) included patient participants from five or more countries. The Delphi survey was
reported as being used singularly or in combination with other methods in 85% (119/140) of projects. Almost a
quarter (16/65) of ongoing studies reported using a combination of qualitative interviews, Delphi survey and
consensus meeting.
Conclusions: These findings indicated that the Delphi survey is the most popular method of facilitating patient
participation, while the combination of qualitative interviews, Delphi survey and consensus meetings is the most
popular combination of methods. The increased inclusion of patient participants in the development of COSs is
encouraging, as is the international approach to COS development that some developers are adopting.
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Background
Evidence enables treatment decisions to be made
according to the needs of the individual patient. This
evidence comes from numerous studies that record and
measure the effects that different illnesses, conditions
and treatments have on patients. These measurements
are known as ‘outcomes’. Outcomes can include quality
of life, treatment costs, fatigue, white blood cell count
and pain. However, across different studies of the same
condition or illness there is considerable variability in
the outcomes measured. This has given rise to difficul-
ties such as: summarising the evidence as the results
cannot be adequately compared and contrasted [1] and
authors selectively reporting outcomes [2]. There is also
the possibility that outcomes currently being measured
may not accurately reflect the priorities of relevant
stakeholder groups, including patients and the public. In
turn, the usefulness of studies in advancing research,
informing clinical practice and empowering clinicians
and patients with knowledge regarding interventions is
limited [3], rendering the research wasteful in many
instances [4, 5].
One answer to this problem is the development of
core outcome sets (COSs). A COS is a minimum set of
agreed standardised outcomes which should be mea-
sured and reported in all trials of a specific condition. It
is considered a fundamental list of outcomes [6], not an
exhaustive list, and researchers can measure additional
outcomes in their trials if they wish [3]. The same set
may also be relevant to systematic reviews of trials. The
Core Outcome Measures in Effectiveness Trials
(COMET) Initiative was launched in 2010 in response to
the recognised value of COS development. COMET aims
to tackle the problem of heterogeneity in reported out-
comes by promoting and facilitating the development
and application of COSs. COMET also collates and stim-
ulates the production of resources for COS develop-
ment, and facilitates the exchange of ideas and
methodological research to enhance the quality and
uptake of COSs. COMET’s key resource is a publicly
accessible database (www.comet-initiative.org) of
planned, ongoing and completed COS studies. The data-
base of published COSs is updated annually via a sys-
tematic review. As indicated by the multiple individuals
and organisations, including trialists, funders, registries,
regulatory authorities, systematic review groups and
journal editors now endorsing the uptake of COSs and
use of the COMET database (a list of these organisations
is available at: www.comet-initiative.org/cosuptake), the
usefulness and importance of this resource, and COS
development more generally, is accepted.
Three stakeholder groups who are important to the
development of all COSs are those who will use the
COSs in research, health professionals and patients, as
recently identified by the consensus-based recommenda-
tions in the Core Outcome Set – STAndards for Devel-
opment: The COS-STAD recommendations [7, 8]. Thus,
the inclusion of patients and the public is key to the
development of COSs [9].
Moreover, to increase reporting completeness and
transparency in COS development COMET have pro-
duced the Core Outcome Set – STAndards for Report-
ing COS-STAR checklist. This checklist states that
authors should describe the participant groups involved,
the rationale for including them and the capacity in
which they participated in the COS development [10].
When using the term ‘patient’ in this article we refer
to patients, carers, health and social care service users
and people from organisations who represent these
groups. Researchers are increasingly including patients
alongside other stakeholders in identifying what out-
comes to measure in clinical trials. While a 2013 system-
atic review found that only 18% of published COS
studies reported patient input [11], subsequent updates
of this review in 2014 and 2015 indicated patient input
in 59% and 61% of published COS developments,
respectively [12, 13]. For most conditions there are many
different outcomes that could be included in a COS.
When patients have not been included in the COS
development process, important outcomes have been
overlooked [14], while other evidence indicates that
patients and families differ in the priority they give to
certain outcomes compared to clinicians [15]. Including
patient participants in deciding which of these outcomes
should be in a COS reduces the danger of omitting
important outcomes. More broadly, patient participation
in COS development enhances the value of research as
it helps to ensure that the outcomes reported are rele-
vant to patients.
However, the best methods for facilitating the par-
ticipation of patients is unknown. There are numer-
ous challenges in enabling participation in a COS
study and these will vary depending on the partici-
pants, the research team and the condition being
researched. The COMET handbook brings together
current thinking and methodological research regard-
ing these challenges [7] including: selecting an appro-
priate recruitment method, finding the best way to
explain the concept of a COS, using a suitable
method to elicit perspectives of patients and health
professionals, maintaining participant input over time,
and enabling the inclusion of patients in face-to-face
meetings with health professionals and academics [9].
Previous COS studies have reported variable rates of
recruitment of participants in the development of the
COS [12], while COS developers have also reported
limited experience of engaging with participants in
the development of important COSs [16].
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This study examined the frequency of patient partici-
pation, which types of patient stakeholder are included,
the methods employed to facilitate patient participation
and the number of countries from which patients have
been sampled in recently published and ongoing COS
projects. By describing the current practice in the devel-
opment of COSs, the survey will help to identify areas
for further improvement and study.
Methods
Design
The survey was conducted in English and included some
brief demographic questions before enquiring about
patient participation in COS development. Patient par-
ticipation was defined as: ‘where patients or the wider
public (family members, carers, health and social care
service users and people from organisations who repre-
sent these groups) or both, take part in the development
of a core outcome set by giving data on their opinions
regarding what outcomes are important.’ A full list of
the questions can be found in Supplementary Informa-
tion: Additional file 1. Survey Questions. The survey was
constructed using the SurveyMonkey software [17]. The
benefits of using this software include the facility to
incorporate filtre questions (whereby depending on the
responses, questions are automatically skipped to the
next appropriate question), it also allowed flexibility in
the answer options which was of vital importance to
obtaining the responses in the most appropriate manner.
A survey was deemed appropriate for this particular
phase of the project as it is inexpensive and allowed us to
engage with a large number of COS developers. Studies
have shown that questionnaire length has a substantial
effect on the number of non-responders [18], this ques-
tionnaire was purposely kept short to avoid this issue and
to not overburden any prospective respondents. Other
factors thought to influence the overall response rate
include readability of questionnaires, such as the number
of syllables per word, words per sentence, typeface and
font size. We therefore followed what is considered best
practice in the academic literature (The National Institute
of Adult Continuing Education guideline ‘Readability:
How to produce a clear written materials for a range of
readers’) when building this survey [18].
Participant selection and recruitment
The COS developers were identified via a search (2 February
2017) of all studies published from 2013 and ongoing COS
projects in the COMET Initiative database.
The survey was sent to COS developers as a link within
a personalised email, inviting them to visit the Survey-
Monkey website where the survey was hosted. Adopting a
personalised approach and follow-up contact with those
who do not respond to the initial email has been
suggested to increase the odds of response by more than a
quarter [18]; therefore, personalised emails were sent and
three further emails were sent to non-responders.
Analysis of survey responses
Responses relating to published COS projects were
validated by reading the appropriate publications
where these were available, and emailing COS devel-
opers for clarification where necessary. The data were
analysed descriptively.
Results
The survey was sent to 192 COS developers. Some devel-
opers were involved in multiple COS projects and we
asked them to complete the survey for each relevant COS.
We contacted 59 developers for 59 published COS pro-
jects, 129 developers for 150 ongoing COS projects and 4
developers for 16 published and 19 ongoing COS projects.
Responses were collected from February until May 2017.
There were 146 respondents yielding a 76% response
rate and providing data regarding 195 projects. The break-
down of respondents and their projects is as follows: 37
responders for 37 published COS projects, 29 responders
for 29 completed COS projects, 49 responders for 52
ongoing COS projects, 25 responders for 27 planned COS
projects, 6 responders for a mixture of 15 published, 12
completed, 17 ongoing and 6 planned COS projects.
Table 1 summarises the frequency of patient participa-
tion in 162 COS projects since 2013, from published,
completed and ongoing studies, after excluding 33 studies
still in the planning stage. Overall, respondents indicated
that 141/162 (87%) COS projects had included patient
participants in the development of their COS (Table 1).
Survey responses for patient participation matched
published information for 51 COSs; in the remaining
published study it was not possible to make this
comparison as the developer did not provide their name
in their survey response. Of 24 published COSs for
which no survey response was received or could be
matched, five (21%) of the journal articles reported
patient participation.
Developers reported input from a variety of patient
stakeholder groups (Table 2): 101 (72%) projects
Table 1 Frequency of patient participation in core outcome set
(COS) projects by COS development stage






Published 14 (27) 38 (73)
Completed 3 (7) 38 (93)
Ongoing 4 (6) 65 (94)
Total 21 (13) 141 (87)
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included both patients (healthcare patients, healthcare
users, consumers, family members, spouse, carers, etc.)
and patient organisations (patient support groups and
patient charity representatives).
For projects including patient participants, Table 3
shows how many countries were involved in the 135
studies where a response was provided. Half of COS
projects included patient participants from only one
country, and this was usually the United Kingdom (41/
70, 59%). Where the study was international, typically
COS developers involved participants from five or more
countries (n = 30/135, 23% of total COSs).
Table 4 summarises COS developers’ responses
regarding the methods that they had used to facilitate
patient participation. Developers responded via a fixed
response option that included five commonly used
methods (Delphi survey, questionnaire, focus group,
qualitative interview and consensus meeting) and an
additional ‘other’ option, which prompted respondents
to state the method in a free-text box. All method com-
binations can be found in Supplementary Information:
Additional file 2. Method Combinations.
As Table 4 shows, the Delphi survey was the most
popular method, having been used singularly or in com-
bination with other methods in over 119 (85%) of the
140 projects with patient participation. A multiple
methods approach was used in 110 (79%) of the 140
projects with patient participation, of which the most
popular method of was the combination of (1) Delphi
survey, qualitative interviews and consensus meeting
(22/140, 16%), followed by (2) Delphi survey singularly
(21/140, 15%). In ongoing studies the most popular
methods used were the combinations of (1) Delphi
survey, consensus meeting and qualitative interviews
(16/65, 25%), followed by (2) Delphi survey, consensus
meeting, focus group and qualitative interviews (9/65,
14%) and finally (3) Delphi survey and consensus
meeting (7/65, 11%).
Discussion
This survey indicates that COS developers are increas-
ingly including patients as participants in COS project
development despite reports of COS developers finding
patient participation difficult to facilitate in comparison
to the participation of other stakeholder groups [16].
While many will welcome the increased inclusion of
patients and patient organisations in COS development,
it could also be argued that patient participants should
exclusively be people who have personal experience of
the condition or situation, as they are best placed to
offer insight into what outcomes are important to some-
one living with a condition. This would exclude people
working for patient organisations as COS study patient
participants or others without personal experience of
what it is like to live with a condition, as their perspec-
tives may be closely aligned with that of a healthcare
professional or researcher. Further research could exam-
ine what should constitute patient participation in COS
development and explore the roles that these groups
have and the similarities and differences in the input
they provide.
The principle behind the development of a COS is that
all researchers working on the same condition, illness or
treatment will use that COS in their research. Therefore,
COSs need to be relevant for use across different coun-
tries if they are to improve the power of research to
benefit patients [9]. The findings of this survey are
encouraging, with several COS projects being run in two
or more countries with patient participants. However,
the majority of COS projects mainly included patient
participants from only one country, usually the UK. Pre-
vious research has indicated that COS developers have
concerns regarding the practicalities and resources sur-
rounding international COS development. Concerns
were also raised in relation to ‘heterogeneity of views
that might arise when participants are included from
Table 2 Frequency of the patient participant groups included
in core outcome set (COS) projects by COS development stage
Stage of COS
development









Published 23 (62a) 14 (38) 0
Completed 28 (74) 10 (26) 0
Ongoing 50 (77) 14 (21) 1 (2)
Total 101 (72) 38 (27) 1 (1)
aNo further information was provided in relation to one published study thus
it has been excluded from further analysis
Table 3 How many patient participant countries are included in core outcome set (COS) development by COS development stage










Published (36) 21 (58) 5 (14) 1 (3) 1 (3) 8 (22)
Completed (36) 13 (36) 6 (17) 5 (14) 3 (8) 9 (25)
Ongoing (63) 36 (57) 10 (16) 2 (3) 2 (3) 13 (21)
Total (135) 70 (52) 21 (16) 8 (6) 6 (4) 30 (22)
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multiple countries’ [16]. Future research could explore
methods of developing COSs with patients and health
professionals from multiple countries in a practical and
feasible manner.
A key challenge in patient participation is enabling
patients to contribute their perspectives in ways that are
meaningful and sustainable. It is vital that the methods
suit the patient group concerned. Patient and public
involvement where patients and the public are involved
as active research partners in a COS project, can provide
a patient and public perspective on the suitability of
different methods from the design to conclusion of a
COS project. The collaboration of researchers and
patient and public involvement partners can help to
ensure the appropriate design and conduct of a COS
project. The survey responses indicated that the use of
combinations of different methods, such as the Delphi
survey, questionnaires, interviews, focus groups and
consensus meetings, is not unusual. It was also evident
that the Delphi survey was the most popular of all
methods of participation in COS development. Delphi
surveys can widen patient participation, promote trans-
parency and offer anonymity. However, these surveys
can be lengthy, and some believe these are intimidating
for patient participants [9]. COS developers have
acknowledged a need for guidance on conducting Delphi
surveys and consensus meetings [16]. The COS-STAD
recommendations identify minimum standards that
should be met during the COS development [8].
A strength of this study was the relatively high
response rate. However, non-response bias is a potential
issue within this survey. The validation work shows non-
respondents for published projects had a lower patient
participation rate than that of those who responded.
This is likely to also be true for non-respondents of
ongoing studies, resulting in an over-estimate of patient
participation reported in the survey. Full and accurate
reporting of COS projects, including details of patient
participation, should continue to improve if developers
use the recently published COS-STAR reporting
guideline [10].
Conclusion
The ongoing inclusion of patient participants in the
development of COSs is encouraging, as is the
international approach that some developers are adopt-
ing, despite the academic literature suggesting that there
are barriers to be overcome in developing international
COS projects.
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Number of COS studies included 37 38 65 140
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